Drugs / PTOC1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07403097 | Feb 2026 → Apr 2028 expected | systemic lupus erythematosus | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTOC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07403097 ↗ |
| Known as | PTOC1 cells Injection | “This is an investigator-initiated trial aimed at assessing the safety and efficacy of PTOC1 cells Injection in the treatment of refractory systemic lupus erythematosus.” NCT07403097 ↗ |